Its settled! The list of Shanghai Shenzhen Hong Kong stock connect is expanded, and the stock of science and technology innovation board is included for the first time

category:Finance
 Its settled! The list of Shanghai Shenzhen Hong Kong stock connect is expanded, and the stock of science and technology innovation board is included for the first time


On the same day, the announcement also said that biotechnology companies listed in Hong Kong would be included in the scope of the Hong Kong stock exchange. Mainland investors will be able to invest in Hong Kongs biotechnology sector.

On November 27, Shanghai and Shenzhen stock exchanges jointly announced that the stock scope of Shanghai Shenzhen Hong Kong stock connect will be expanded.

On the same day, the Shanghai Stock Exchange and China Securities Index Co., Ltd. announced that they would adjust the samples of Shanghai Stock Exchange 180, Shanghai Stock 380 and other indexes. The adjustment took effect on December 14. At that time, Shanghai Stock Exchange 180, Shanghai Shenzhen 300 and other scale indexes are expected to appear for the first time.

From the list, the company will be transferred into the sample of Shanghai Stock Exchange 180 index. RuiChuang micro nano, Hangke technology, LanChi technology, Anji technology, Western superconductor and Haier biology will be transferred into Shanghai Stock 380 index.

According to the Shanghai Stock Exchange, in order to further enhance the influence of the science and technology innovation board, introduce more medium and long-term funds, and provide investment channels for small and medium-sized investors, it is imperative that science and technology innovation board securities be included in the component index.

According to the Shanghai Stock Exchange, extensive market research at home and abroad shows that institutional investors have a positive attitude towards the selection of sci tech Innovation Board securities in Shanghai Stock Exchange 180, Shanghai Shenzhen 300 and other component indexes.

It should be noted that, in view of the implementation of investor suitability management on the science and technology innovation board, investors who buy and sell stocks on the board through the Shanghai Stock connect are intended to be limited to institutional professional investors defined in accordance with the relevant rules of Hong Kong. The rules are subject to approval by regulators in both places, the exchange said.

In the next step, Shanghai Shenzhen Hong Kong Stock Exchange will actively promote relevant business technology preparation. It is expected that after the market preparation work is completed in early 2021, the relevant sci tech Innovation Board stocks will be included in the stock scope of Shanghai Shenzhen Hong Kong stock connect.

Hong Kong listed biotechnology companies become new targets in a month

At the same time, the Shanghai, Shenzhen and Hong Kong stock exchanges have agreed through consensus that for the shares of biotechnology companies listed in section 18a of the main board listing rules of the stock exchange of Hong Kong Limited, if they belong to the relevant Hang Seng Composite Index or H shares of a + H listed company listed on the Shanghai Shenzhen Hong Kong stock exchange, the shares will be transferred into the stock scope of the Hong Kong stock connect according to the existing provisions of the Shanghai Shenzhen Hong Kong stock connect (the shares of biotechnology companies belonging to the a + H-share companies of the science and Technology Innovation Board will be transferred into the stock scope of Hong Kong stock exchange according to the above arrangement of the shares of the science and technology innovation board).

Previously, the chief executive officer of the Hong Kong stock exchange, Li Xiaojia, pointed out that Hong Kong shares may become the worlds largest biotechnology IPO market in the future. According to PricewaterhouseCoopers, the new economy and biotechnology companies will be the main driving force for listing activities on the Hong Kong Stock Exchange in the second half of 2020. It is expected that more than 10 biotechnology enterprises will be listed successfully on the Hong Kong Stock Exchange in the whole of 2020. Under the interconnection mechanism, the Hong Kong stock biotechnology target is expected to welcome the favor of mainland investors. It is understood that in the next step, Shanghai Shenzhen Hong Kong Stock Exchange will actively promote the completion of relevant market preparations. It is expected that the shares of the above biotechnology companies will be included in the scope of Hong Kong stock connect one month from the date of the announcement on the 27th. Biotech companies that do not have the B symbol at the end of their share names and are already Hong Kong stock connect shares at the time of the announcement will not be affected. The exchange said that in the future, the three exchanges of Shanghai, Shenzhen and Hong Kong will continue to cooperate closely, continuously optimize the interconnection mechanism, and promote the coordinated, stable and healthy development of the two capital markets. Source of this article: Zhong Qiming, editor in charge of securities companies in China_ NF5619

Previously, the chief executive officer of the Hong Kong stock exchange, Li Xiaojia, pointed out that Hong Kong shares may become the worlds largest biotechnology IPO market in the future. According to PricewaterhouseCoopers, the new economy and biotechnology companies will be the main driving force for listing activities on the Hong Kong Stock Exchange in the second half of 2020. It is expected that more than 10 biotechnology enterprises will be listed successfully on the Hong Kong Stock Exchange in the whole of 2020. Under the interconnection mechanism, the Hong Kong stock biotechnology target is expected to welcome the favor of mainland investors.

It is understood that in the next step, Shanghai Shenzhen Hong Kong Stock Exchange will actively promote the completion of relevant market preparations. It is expected that the shares of the above biotechnology companies will be included in the scope of Hong Kong stock connect one month from the date of the announcement on the 27th. Biotech companies that do not have the B symbol at the end of their share names and are already Hong Kong stock connect shares at the time of the announcement will not be affected.

The exchange said that in the future, the three exchanges of Shanghai, Shenzhen and Hong Kong will continue to cooperate closely, continuously optimize the interconnection mechanism, and promote the coordinated, stable and healthy development of the two capital markets.